HTG Molecular Diagnostics (HTGM) Receives a Buy from H.C. Wainwright


H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on HTG Molecular Diagnostics (NASDAQ: HTGM) today and set a price target of $7. The company’s shares closed yesterday at $3.31.

Selvaraju wrote:

“We believe HTG could launch additional new panels in 4Q18. In the wake of this update, we reiterate our Buy rating and $7 price target.”

According to TipRanks.com, Selvaraju ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -4.3% and a 35.0% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.

HTG Molecular Diagnostics has an analyst consensus of Moderate Buy, with a price target consensus of $7.

See today’s analyst top recommended stocks >>

The company has a one-year high of $5.83 and a one-year low of $1.59. Currently, HTG Molecular Diagnostics has an average volume of 416.7K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

HTG Molecular Diagnostics, Inc. engages in the provision of molecular technology solutions that facilitates molecular profiling. Its customers include biopharmaceutical companies, academic research centers, and molecular testing laboratories. The company was founded by Bruce E. Seligmann in October 1997 and is headquartered in Tucson, AZ.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts